Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

7.4K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
7.4K
Clinical Applications of Epidermal Stem Cells01:19

Clinical Applications of Epidermal Stem Cells

2.7K
Epidermal stem cells (EpiSCs) are mainly located at the basal layer of the epidermis. These cells repair minor injuries of the skin and replace dead skin cells. However, EpiSCs’ cannot heal severe wounds such as major burns or those from diabetes or hereditary disorders. In such cases, culturing the epidermal stem cells from the patient is possible and has yielded successful treatment options, such as laboratory-grown skin grafts. These grafts are synthesized using a patient’s own...
2.7K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

6.8K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.8K
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

461
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
461
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

451
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
451

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hormonal Dysregulation and Neuroinflammation in Endometriosis: Convergent Druggable Pathways.

Current issues in molecular biology·2026
Same author

Inhibition of Diabetes-Related Enzymes by Plant Secondary Metabolites: A Promising Therapeutic Strategy.

Life (Basel, Switzerland)·2026
Same author

Synthesis, Characterization and Toxicity Evaluation of Some New Heterocyclic Compounds from Oxazole and 1,2,4-Triazine Classes.

Molecules (Basel, Switzerland)·2026
Same author

Design, Synthesis, Spectral, Structural Analysis, and Biological Evaluation of Novel Pyrazole Derivatives as Anti-Tumor, Antimicrobial, and Anti-Biofilm Agents.

Antibiotics (Basel, Switzerland)·2026
Same author

Phytochemical Screening and Physicochemical Properties of Oil Extract of <i>Usnea barbata</i> L. F.H.Wigg from Călimani Mountains, Romania.

International journal of molecular sciences·2026
Same author

Modulation of Toll-like Receptors with Natural Compounds: A Therapeutic Avenue Against Inflammaging?

International journal of molecular sciences·2025

Related Experiment Video

Updated: Sep 10, 2025

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach
09:32

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach

Published on: September 26, 2019

7.3K

Targeting Intracellular Pathways in Atopic Dermatitis with Small Molecule Therapeutics.

Georgiana Nitulescu1, Octavian Tudorel Olaru1, Corina Andrei1

  • 1Faculty of Pharmacy, "Carol Davila" University of Medicine and Pharmacy, Traian Vuia 6, 020956 Bucharest, Romania.

Current Issues in Molecular Biology
|August 27, 2025
PubMed
Summary
This summary is machine-generated.

New small molecule therapies offer promising oral or topical alternatives for atopic dermatitis (AD) management, targeting key pathways in this chronic inflammatory skin condition.

Keywords:
Janus kinase inhibitorSTAT6 degraderaryl hydrocarbon receptor ligandclinical trialshistamine H4 receptor antagonistphosphodiesterase 4 inhibitorprecision dermatologysphingosine-1-phosphate receptor modulatortargeted immunomodulatortype 2 inflammation targeting

More Related Videos

Author Spotlight: Effective Reuse of Polycarbonate Tubes for Extracellular Vesicle Isolation
02:36

Author Spotlight: Effective Reuse of Polycarbonate Tubes for Extracellular Vesicle Isolation

Published on: March 8, 2024

1.1K
Author Spotlight: Exploring ShiDuGao's Multi-Target Approach in Anus Eczema Treatment
12:34

Author Spotlight: Exploring ShiDuGao's Multi-Target Approach in Anus Eczema Treatment

Published on: January 12, 2024

898

Related Experiment Videos

Last Updated: Sep 10, 2025

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach
09:32

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach

Published on: September 26, 2019

7.3K
Author Spotlight: Effective Reuse of Polycarbonate Tubes for Extracellular Vesicle Isolation
02:36

Author Spotlight: Effective Reuse of Polycarbonate Tubes for Extracellular Vesicle Isolation

Published on: March 8, 2024

1.1K
Author Spotlight: Exploring ShiDuGao's Multi-Target Approach in Anus Eczema Treatment
12:34

Author Spotlight: Exploring ShiDuGao's Multi-Target Approach in Anus Eczema Treatment

Published on: January 12, 2024

898

Area of Science:

  • Dermatology and Immunology
  • Pharmacology
  • Drug Discovery

Background:

  • Atopic dermatitis (AD) is a chronic inflammatory skin disease with immune dysregulation and barrier dysfunction.
  • Biologic therapies have advanced AD treatment but face challenges in cost, administration, and accessibility.
  • Small molecule therapies are emerging as targeted, potentially more accessible treatment options.

Purpose of the Study:

  • To review emerging small molecule therapies for moderate-to-severe atopic dermatitis.
  • To analyze their mechanisms of action, clinical data, and therapeutic potential.
  • To discuss safety, tolerability, and future integration into precision medicine.

Main Methods:

  • Comprehensive literature review of small molecule agents for atopic dermatitis.
  • Analysis of pharmacological profiles and pivotal clinical trial data.
  • Evaluation of safety and tolerability data.

Main Results:

  • Several classes of small molecules, including JAK inhibitors, PDE4 inhibitors, and others, show promise.
  • These agents target intracellular pathways critical to AD pathogenesis.
  • Clinical data suggest potential for addressing unmet needs in AD treatment.

Conclusions:

  • Small molecule therapies offer diverse mechanisms and administration routes for atopic dermatitis.
  • Further research and clinical trials are needed to establish long-term safety and efficacy.
  • These agents represent a significant advancement in precision treatment strategies for AD.